Home respiratory care set to take off – Chinadaily.com.cn
Home respiratory care set to take off
By Li Jing |
China Daily |
Updated: 2026-07-22 09:05<img src="https://healthylife7.com/wp-content/uploads/2026/07/twitter-3.png” alt=””>
Share – WeChat
China is shifting chronic respiratory disease management beyond hospitals toward home-based care, as policymakers, clinicians and medical-device makers promote earlier screening and long-term digital monitoring, creating new opportunities in one of the country’s fastest-growing healthcare markets
The move reflects a broader effort to address one of China’s biggest chronic disease burdens while easing pressure on the country’s healthcare systems as the population ages. Nearly 100 million people suffer from chronic obstructive pulmonary disease (COPD), while an estimated 176 million have obstructive sleep apnea (OSA), according to data cited in newly released recommendations jointly issued by the China-Japan Friendship Hospital, MD Weekly and a multidisciplinary expert committee
The recommendations, based on nationwide surveys of 1,000 members of the public and 319 physicians, call for a shift from hospital-centered treatment to continuous disease management spanning public awareness, early screening, standardized diagnosis, home therapy and long-term follow-up
The recommendations build on a series of healthcare reforms aimed at shifting chronic disease management toward primary care and community-based services. The Healthy China initiative, a comprehensive public health strategy launched in 2019, identified chronic respiratory diseases as a national public health priority, while COPD was incorporated into the national basic public health service program in 2024, further expanding community-based management and early screening
“These diseases require lifelong management rather than one-off treatment,” said Zhang Xiaolei, a senior respiratory physician at China-Japan Friendship Hospital. “Patients need continuous follow-up after leaving hospital, and digital technologies are making that increasingly feasible through remote monitoring and home-based management.”
Delayed diagnosis remains a critical barrier. Many patients dismiss persistent snoring, chronic coughing or breathlessness as signs of aging rather than symptoms of chronic disease. The recommendations found that nearly half of OSA patients delayed seeking medical attention for more than one year, while many COPD patients were diagnosed only after significant lung-function impairment had already occurred
Home-based management becomes an increasingly important part of respiratory care. The recommendations advocate integrating home monitoring devices, remote follow-up and digital health platforms into routine treatment so patients remain under medical supervision after leaving hospital rather than relying solely on periodic outpatient visits
European sleep specialists said the direction mirrors broader international practice. “For standard cases, home monitoring will really be enough,” said Raphael Heinzer, director of the Center for Investigation and Research in Sleep at Lausanne University Hospital in Switzerland
Home sleep recordings can diagnose most routine obstructive sleep apnea cases before physicians review the results and prescribe treatment, although specialized hospital sleep laboratories remain necessary for more complex conditions, he said
The transition is also reshaping the commercial landscape for respiratory care
Respiratory medicines generated nearly 62 billion yuan ($9.16 billion) across hospitals, retail pharmacies and online pharmacies in China in 2024, with COPD and asthma therapies accounting for more than three-quarters of the market, according to pharmaceutical data provider Menet
Demand is increasingly shifting toward home-use devices. China’s home respiratory disease management equipment market — including non-invasive ventilators for home use, oxygen concentrators, nebulizers and portable lung-function monitors — was estimated at 8.93 billion yuan in 2025, up 14.8 percent from a year earlier, according to Frost & Sullivan and industry estimates. Non-invasive ventilators for home use accounted for about one-third of the market, while domestic manufacturers now control more than 60 percent of sales.
The industry’s focus is increasingly shifting beyond hardware sales toward long-term disease management supported by cloud platforms, remote monitoring and AI-enabled software. BMC Medical, one of China’s major manufacturers of respiratory health devices, has expanded cloud-based management services that allow physicians to remotely review patients’ treatment data, adjust ventilation settings and conduct follow-ups outside hospitals. It is also incorporating AI into home respiratory devices to support personalized treatment and long-term patient follow-up.
European specialists suggest that China’s combination of a large patient population and rapid adoption of digital healthcare could create opportunities for joint research. Frederic Gagnadoux, head of respiratory and sleep medicine at Angers University Hospital in France, said China’s clinical scale offers significant potential for international multicenter studies, potentially helping researchers better understand various forms of OSA and the long-term impact of treatment on cardiovascular health and quality of life.
Photo
In Photos: 2026 WIC Digital Silk Road Development Forum opens in Xi’an
Wuhan air conditioner shipments to Europe soar 88% in June
Round-up of 2026 China Storyteller Partnerships tour in Henan
World’s highest solar thermal power plant completes mirror installation
Global guests discover Henan’s allure
China-US economic ties: The path ahead
Most Viewed in 24 Hours
‘);
/*]]>*/
State Council News
A look at China’s economy in H1 of 2026
China’s economy in first half, 2026
Top 10
Top 10 countries attracting Chinese tourists
Business focus
Guangdong to scale up future industry drive
Hainan Free Trade Port a global launchpad
China Data
Xinjiang’s green power trading volume hits record high
SOEs
SOEs return more profits to State
China’s central SOEs invest 1.1t yuan in Xinjiang during 14th Five-Year Plan period
Special
China International Supply Chain Expo
2026 Summer Davos
BACK TO THE TOP
English
中文
Copyright 1994 – . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263
Registration Number: 130349 
About China Daily
Advertise on Site
Contact Us
Job Offer
Expat Employment
FOLLOW US
